We are pleased to announce that Toni Andreu will stay on as EATRIS Scientific Director for a further five years. The decision was unanimously approved as part of the Board of Governors Meeting in Malaga, Spain on 10 May 2022. The Board expressed their gratitude to Toni for his leadership in the first period, and his commitment to lead EATRIS in this next chapter as the organisation further enhances the translational medicine ecosystem for the benefit of patients.
Speaking about his second term, Toni says: “As you can imagine, this represents an important moment for me, both professionally and personally as my journey with the organisation will continue for five additional years. It is an opportunity to work with an amazing community of members, doing our best to create something that is a game changer in offering solutions that alleviate human suffering.”
Håkan Billig (Chair of the EATRIS Board of Governors) said the following about Toni’s confirmed second period as EATRIS Scientific Director: “We are pleased to appoint Toni Andreu for a further five years as the EATRIS Scientific Director. We are grateful to Toni for his leadership since 2018 and the Member States look forward to working with him in the years ahead as the organisation continues to accelerate the translation of biomedical discoveries into patient benefit.“
Anton Ussi (EATRIS Operations & Finance Director) added the following: “We are really excited to continue this remarkable journey with Toni. We have achieved so much under his decisive scientific leadership, yet have so much still to do for optimal human health and biomedical innovation in Europe. Toni is the perfect scientist, leader and visionary to help us achieve our important mission.”
Toni’s first term ran from 2018 to 2022, and his second 5-year period will run from 2023 to 2027.